Danaher (DHR) has drawn investor attention after recent share price moves, including a gain of about 10% over the past month and roughly 18% over the past 3 months. This has prompted closer review of its fundamentals.

Over the past year, Danaher has delivered a 5.75% total shareholder return. The share price is currently at $216.07 after recent 1 month and 3 month share price returns of about 10% and 18% respectively, which suggests momentum has picked up recently after earlier year to date weakness.

Compare Danaher's recent momentum with a hand picked group of companies by scanning the 44 high quality undervalued stocks that may also be catching a bid after earlier weakness.

After that rebound and with Danaher at about $216, the question now is whether the recent optimism still leaves a margin of comfort for new buyers. It is time to see what the current valuation is asking you to pay for.

Most Popular Narrative: 6% Undervalued

The most followed narrative currently places Danaher’s fair value at about $228.61, which is modestly above the recent $216.07 share price and frames today’s optimism as only partially reflected in the stock.

The sustained advancement of precision medicine and personalized therapies, including new AI-assisted diagnostic solutions and groundbreaking launches in genomics (like support for in vivo CRISPR therapies), positions Danaher's technology portfolio to capture higher-margin growth and drive long-term EBITDA expansion.

Read the complete narrative. Read the complete narrative.

Want to see what sits behind that premium toolkit story for Danaher? The narrative focuses on recurring consumables, rising margins, and a future earnings power that needs to line up with those higher quality expectations. The full set of assumptions shows how all of that feeds into the fair value line.

Result: Fair Value of $228.61 (UNDERVALUED)

However, investors also need to weigh risks for Danaher, including softer genomics and life science instrument demand, as well as ongoing policy pressure in key markets like China.

Another View: What Danaher’s P/E Is Telling You

The earlier fair value work suggests Danaher is about 4.9% below an estimated value, yet the current 38.1x P/E is higher than both the fair ratio of 29.2x and the peer average of 33.5x. That premium points to valuation risk. Is the quality story strong enough to justify it?

See what the numbers say about this price in our valuation breakdown. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on valuation, growth, and quality around Danaher, it makes sense to move quickly and weigh the evidence for yourself using the 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Danaher?

If Danaher has your attention, do not stop here. Broaden your watchlist with other clear ideas that could strengthen your overall portfolio.

• Target dependable income streams by reviewing the 12 dividend fortresses and see which companies align with your yield goals.
• Spot potential mispricings early using the 19 high quality undiscovered gems that combine stronger fundamentals with less crowding from other investors.
• Strengthen capital protection by assessing the 74 resilient stocks with low risk scores that aim to balance return potential with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.